Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome
Authors
Keywords
Breast cancer, Distant metastases, Subtypes, Prognosis, Survival
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 141, Issue 3, Pages 507-514
Publisher
Springer Nature
Online
2013-10-08
DOI
10.1007/s10549-013-2711-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 1st International consensus guidelines for advanced breast cancer (ABC 1)
- (2012) F. Cardoso et al. BREAST
- Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases
- (2012) Laurien D. C. Hoefnagel et al. CANCER
- Testing for Discordance at Metastatic Relapse: Does It Matter?
- (2012) Stephen Chia JOURNAL OF CLINICAL ONCOLOGY
- Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?
- (2012) Alan S. Coates et al. JOURNAL OF CLINICAL ONCOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Factors associated with mortality after breast cancer metastasis
- (2011) Su Yon Jung et al. CANCER CAUSES & CONTROL
- Prognostic Value of Initial Tumor Parameters After Metastatic Relapse
- (2011) E. Planchat et al. CANCER INVESTIGATION
- Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies
- (2011) Eitan Amir et al. CANCER TREATMENT REVIEWS
- Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: A retrospective clinical study
- (2011) P. Sanpaolo et al. EJSO
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
- (2011) Naoki Niikura et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer
- (2011) Eitan Amir et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
- (2010) Katrina Bauer et al. BMC CANCER
- Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register
- (2010) Javier Puente et al. BREAST CANCER RESEARCH AND TREATMENT
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Behavior of Breast Cancer Subtypes
- (2010) Hagen Kennecke et al. JOURNAL OF CLINICAL ONCOLOGY
- Third consensus on medical treatment of metastatic breast cancer
- (2009) S. Beslija et al. ANNALS OF ONCOLOGY
- Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
- (2009) C. Liedtke et al. ANNALS OF ONCOLOGY
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factors in 1038 women with metastatic breast cancer
- (2008) R. Largillier et al. ANNALS OF ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now